Letter to the editor
Successful cure of C1q deficiency in human subjects treated with hematopoietic stem cell transplantation

https://doi.org/10.1016/j.jaci.2013.07.035Get rights and content

First page preview

First page preview
Click to open first page preview

References (6)

  • M. Botto et al.

    Complement in human diseases: lessons from complement deficiencies

    Mol Immunol

    (2009)
  • G. Vassallo et al.

    Clinical variability and characteristic autoantibody profile in primary C1q complement deficiency

    Rheumatology

    (2007)
  • S.H. Sacks et al.

    The role of complement in the early immune response to transplantation

    Nat Rev Immunol

    (2012)
There are more references available in the full text version of this article.

Cited by (57)

  • Inborn Errors of Immunity and Autoimmune Disease

    2023, Journal of Allergy and Clinical Immunology: In Practice
  • Intertwined pathways of complement activation command the pathogenesis of lupus nephritis

    2022, Translational Research
    Citation Excerpt :

    C1q antibodies in SLE patients are associated with proliferative LN, and may specify the activity of renal disease.70 Therapeutic success was achieved using fresh frozen plasma or hematopoietic stem cell transplantation to treat C1q-deficient SLE patients.71,72 Taken together, the human and mouse data advise that specific modulation of the classical pathway using inhibitors or activators of complement may reduce the kidney damage associated with LN.

View all citing articles on Scopus

Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.

View full text